Further Information
PLAU, plasminogen activator, urokinase, HGNC:9052, ATF, UPA, URK, u-PA, U-plasminogen activator, antagonist of uPA, urinary, urokinase plasminogen activator, urokinase-type plasminogen activator amino-terminal fragment, urokinase-t, QPD, BDPLT5
WB: 1:500 - 1:2000
This gene encodes a secreted serine protease that converts plasminogen to plasmin. The encoded preproprotein is proteolytically processed to generate A and B polypeptide chains. These chains associate via a single disulfide bond to form the catalytically inactive high molecular weight urokinase-type plasminogen activator (HMW-uPA). HMW-uPA can be further processed into the catalytically active low molecular weight urokinase-type plasminogen activator (LMW-uPA). This low molecular weight form does not bind to the urokinase-type plasminogen activator receptor. Mutations in this gene may be associated with Quebec platelet disorder and late-onset Alzheimer's disease. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed.
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
batch dependent
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Recombinant fusion protein containing a sequence corresponding to amino acids 20-180 of human PLAU (NP_002649.1).
5328
plasminogen activator, urokinase
PLAU
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
Observed: 49kDa
Affinity purification
Cancer, Neuroscience, Signal Transduction
P00749
Optimal dilutions for each application to be determined by the researcher.